[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Göteborg University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":645},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,48,80,111,137,171,194,222,249,274,298,317,341,362,381,401,424,450,474,496,520,547,578,605,627],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100643424","health-effects-of-ultra-processed-food-intake-100643424",false,"NCT07634159","Health Effects of Ultra-processed Food Intake","Health Effects of Ultra-processed Food Intake: a Randomized Crossover Feeding Study","UPFront","Inclusion Criteria:\n\n* Age 20-60 years\n* Weight stable (less than 5% weight change in the past 3 months)\n* No plans to change weight\n* Willing to eat the study diet and a mixed diet\n* Has provided informed consent to participate in the study\n\nExclusion Criteria:\n\n* Allergy or intolerance to foods included in the study. Participants with lactose intolerance treated with lactase may participate if they take enzymes.\n* BMI \\\u003C18.5 or \\>35 kg\u002Fm²\n* Use of medications known to significantly affect appetite (e.g., oral corticosteroids, antipsychotic medications, or GLP-1 receptor agonists)\n* Use of lipid-lowering medications (e.g., statins or PCSK9 inhibitors)\n* Diagnosed diabetes or capillary blood glucose at or above 12.2 mmol\u002FL\n* Disease associated with malabsorption (e.g., inflammatory bowel disease or celiac disease)\n* Previous bariatric surgery\n* Established cardiovascular disease (heart failure, myocardial infarction, or stroke) or cancer\n* Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study",true,"ALL","20 Years","60 Years",{"count":23,"type":24},40,"ESTIMATED","INTERVENTIONAL",[27],"NA","Ultra-processed food (UPF) intake has been related to negative health effects and incresed energy intake in previous intervention studies. Thus, previous studies have seen weight gain from higher UPF intake which obscures the potentital to see effects on cardiometabolic biomarkers, independent of weight changes. The overall aim of this project is to study the causal effects of a high UPF diet, compared to a nutrient-matched low UPF diet, on appetite and cardiometabolic health in a weight-stable context.",[30,31,32],"Cardiometabolic Risk Factors","Microbiota","Diet Interventions",[34],"Ultra-processed food","NOT_YET_RECRUITING","2026-06-03",{"date":38,"type":39},"2026-06-08","ACTUAL",{"date":41,"type":24},"2026-08",{"date":43,"type":24},"2027-12",{"name":45,"class":46},"Göteborg University","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":18,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":25,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":47},"100639586","the-effects-of-nitrate-rich-mouthwash-on-vascular-tone-100639586","NCT07602764","The Effects of Nitrate-Rich Mouthwash on Vascular Tone","The Short-Term Effects of Nitrate-Rich Mouthwash on Oral Bacterial Nitrite Production, Blood Pressure, and Nitrate and Nitrite Concentrations in Plasma and Saliva of Healthy Adults","NITRATONE","Inclusion Criteria:\n\n* ≥18 years of age; and\n* clinic blood pressure \\\u003C140\u002F\\\u003C90 mmHg.\n\nExclusion criteria:\n\n* hypertension;\n* systemic medication (other than the oral contraceptive pill);\n* antibiotic treatment within the last 3 months;\n* active smoking status and BMI \\> 30;\n* prior gastric by-pass surgery;\n* self-reported use of antiseptic mouthwash or toothpaste;\n* self-reported use of tongue scrapes; and\n* active periodontal disease or caries that needs treatment.","18 Years",{"count":58,"type":24},20,[27],"High blood pressure (hypertension) is a major risk factor for cardiovascular disease. One important contributing factor to high blood pressure is reduced availability of nitric oxide (NO). Therefore, NO is an important molecule in maintaining healthy blood vessel function.\n\nDietary nitrate, found in leafy greens, can serve as an alternative source of nitric oxide in the body. After ingestion, nitrate is converted to nitrite by bacteria residing in the oral cavity. Nitrite can subsequently be converted to NO when swallowed. Therefore, this nitrate-nitrite-nitric oxide pathway is dependent on oral bacteria.\n\nThis study aims to assess whether rinsing the mouth with a nitrate-rich mouth rinse influences blood pressure in healthy adults. Also, concentrations of nitrate and nitrite in plasma and saliva will be measured following the nitrate-mouth rinse exposure.",[62],"Blood Pressure Regulation",[64,65,66,67,68,69,70,71],"Nitrate reduction","Nitrate supplement","Blood pressure regulation","Plasma nitrate","Plasma nitrite","Saliva nitrate","Saliva nitrite","Mouth rinse","2026-05-19",{"date":74,"type":39},"2026-05-22",{"date":76,"type":24},"2026-04",{"date":78,"type":24},"2028-12",{"name":45,"class":46},{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":47},"100635361","pleasant-touch-perception-in-persistent-pain-100635361","NCT07551687","Pleasant Touch Perception in Persistent Pain.","Being Touched in Persistent Pain: Mapping the Association Between Pleasant Touch and Central Sensitization in Patients With Persistent Pain.","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Referred to and accepted for assessment at Pain Clinic (Smärtteam) Västra Götaland due to persistent pain (duration ≥ 3 months)\n* Able to read and complete self-report questionnaires in Swedish\n\nExclusion Criteria:\n\n* Inability to read or complete self-report questionnaires in Swedish\n* Need for interpreter support",{"count":88,"type":24},100,"OBSERVATIONAL","The goal of this observational study is to learn how individuals with chronic pain experience pleasant touch and how often they are exposed to such touch in their daily lives. The study also aims to examine how these experiences relate to pain sensitivity and body awareness. The main questions it aims to answer are:\n\nHow is the perception of pleasant touch associated with central sensitization and interoceptive awareness in individuals with chronic pain?\n\nDoes the perception of pleasant touch differ between individuals with different dominant pain mechanisms (nociceptive, neuropathic, and nociplastic)?\n\nParticipants referred to a specialist Pain Clinic in Västra Götaland as part of their regular care will be invited to take part. Those who consent will complete online questionnaires assessing pain, experience and exposure to touch, interoceptive awareness, and central sensitization. Clinical data such as pain diagnosis and medical history will also be collected.",[92,93],"Chronic Pain","Persistent Pain",[95,96,97,98,99,100,101,102],"Nociplastic pain","Neuropathic pain","Nociceptive pain","Pleasant touch","Central sensitization","Interoception","Social touch","Affective touch","2026-04-20",{"date":105,"type":39},"2026-04-27",{"date":107,"type":24},"2026-04-26",{"date":109,"type":24},"2030-02-01",{"name":45,"class":46},{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100623806","life-sustaining-treatments-in-critically-ill-children-100623806","NCT07401420","Life Sustaining Treatments in Critically Ill Children","Project Plan Physicians' Experiences of the Decision-making Process Regarding Decisions to Withhold\u002FDiscontinue Life-sustaining Treatment in Children Cared for in Intensive Care Units in Sweden. A Qualitative Study.","LST-Ped-Int","Inclusion Criteria:\n\n* Specialist physicians in critical care with experience from end of life care in critically ill children.\n\nExclusion Criteria:\n\nNone\n\n\\-",{"count":120,"type":24},30,"Summary of the Research on Withdrawing and Withholding Life-Sustaining Treatment for Critically Ill Children Background Medical treatments require regular evaluation to ensure they align with the patient's best interests, particularly in intensive care where quality of life is often compromised. In the context of critically ill children, the challenge increases as patients may not be fully conscious or capable of expressing their needs and preferences. While intensive care can extend life, end-of-life situations necessitate careful consideration to avoid providing futile treatments that do not benefit the patient.\n\nDecision-Making Complexity Identifying when further treatment is beneficial poses significant challenges, influenced by various factors including the wishes of the patient and guardians. Previous studies indicate variability among healthcare providers in treatment decisions, often stemming from personal experiences and emotional responses. However, comparable research focusing on critically ill children in Nordic contexts remains scarce. Medical decisions often require balancing potential benefits against the risks of extended suffering or loss of valuable time at the end of life.\n\nA previous survey on end-of-life care in Europe indicated similar attitudes across regions but highlighted the need for cultural considerations. Sweden's distinct social and cultural values, characterized by individualism and secularism, may influence practices surrounding life-sustaining treatment.\n\nResearch Aims This research aims to investigate the factors affecting decision-making regarding the withdrawal and withholding of life-sustaining treatments for critically ill children in Swedish and Nordic intensive care units (ICUs). It will examine practitioners' experiences, attitudes, and the relative impact of children's autonomy in these decisions, excluding neonatal care.\n\nKey scientific questions focus on Physicians' attitudes and challenges regarding treatment withdrawal.\n\nMethodology\n\nSemi-structured interviews in multiple ICUs to explore ethical dilemmas faced by physicians.",[123,124,125],"Critical Illness","Ethics","End of Life Care",[127,124,128],"Critical illness","End of life care","2026-02-06",{"date":131,"type":39},"2026-02-10",{"date":133,"type":24},"2026-02-01",{"date":135,"type":24},"2027-12-31",{"name":45,"class":46},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":25,"phases":147,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},"100343846","effects-of-an-opioid-freesparing-care-pathway-for-patients-undergoing-obesity-surgery-100343846","NCT03756961","Effects of an Opioid Free\u002FSparing Care Pathway for Patients Undergoing Obesity Surgery","Effects of an Opioid Sparing Care Pathway for Patients Undergoing Obesity Surgery","OS-PCC","Inclusion Criteria:\n\n-Patients ≥18 years planned to undergo laparoscopic obesity surgery (GBP alt Sleeve surgery) at the selected site.\n\nExclusion Criteria:\n\n* ASA\\> III\n* Cardiovascular disease with bradycardia (\\\u003C50 bpm)\n* Serious liver disease failure\n* Insufficient knowledge of the Swedish language\n* Serious untreated psychiatric disease\n* Neurocognitive dysfunction\n* Pregnancy\n* Women of childbearing age without contraception\n* Malignant disease with expected short survival\n* Patients treated with opioids for chronic pain\n* Substance abuse\n* Hypersensitivity to Oxycodone, Esketamine, Dexmedetomidine, and Lidocaine\n* Pacemaker or ICD\n* Inability to fill in questionnaires\n* Decline participation,",{"count":146,"type":24},220,[27],"The opioid consumption has exploded in the western world, and for some patient populations such as obese patients, patients with sleep apnoea or patients undergoing cancer treatment, opioid-sparing\u002F opioid-free strategies could have positive effects on outcomes. Studies suggest that opioids could have opioid-induced immunosuppression, induce chronic post-operative pain syndrome and hyperalgesia in addition to the more well-known side effects such as respiratory depression, nausea, bladder, and bowel dysfunction. Hence, new studies are needed on the impact of person-centered care programs that combine pharmaceutical and non-pharmaceutical strategies to reduce the adverse short and long-term effects of opioid therapy.\n\nThe overall aim is to evaluate the short-, medium- and long-term effects of opioid-free care pathways with or without person-centred care compared to conventional opioid-based treatment in patients undergoing obesity surgery.\n\nSpecific aims\n\n1. Determine the effects of opioid-free care with or without person-centred care compared with conventional opioid-based general anaesthesia on the cognitive and physical quality of recovery after surgery up to 24 months after surgery (short-term: postoperative to discharge, medium-term: 14 days, 3 months, long-term: 6 months, 12 months and 24 months).\n2. Describe the clinical monitoring trend regarding nociceptive response intraoperatively between opioid-free and conventional care.\n3. Map the impact of opioid-free anaesthesia (with and without person-centred care) on the usage of opioids up to 24 months after hospital discharge.\n4. Explore the patients' experience of quality of life, economic evaluations, self-efficacy and recovery after surgery in opioid-free care with or without person-centred care during the first year post-surgery.\n\nThe aims will be evaluated by a prospective, randomized, non-blinded, non-commercial multi-centre study (Nov 2018-Dec 2022) approved by the Swedish Medicines Agency (EU-CT 2023-505934-86-00) and the ethical review board (DNR 1006-17).",[150,151],"Obesity","Pain, Postoperative",[153,154,155,156,157,158,159,160],"opioids","bariatric surgery","anesthesia","opioid-free","person-centred care","recovery","TENS","pain","RECRUITING","2026-01-02",{"date":164,"type":39},"2026-01-07",{"date":166,"type":39},"2019-05-01",{"date":168,"type":24},"2029-12-31",{"name":45,"class":46},2,{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":18,"sex":19,"minAge":56,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":25,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":47},"100609335","metabolic-effects-of-short-term-ultra-processed-food-intake-mest-upf-100609335","NCT07213245","Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF)","Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF): a Randomized Controlled Trial","Inclusion Criteria:\n\n* Body mass index (BMI) 18.5-30 kg\u002Fm2\n* Fasting glucose \\\u003C 6.1 mmol\u002Fl\n* Hb \\>110 g\u002FL\n* Weight stability the last 3 months +\u002F-5%\n\nExclusion Criteria:\n\n* Food allergies, intolerances or preferences preventing consumption of any products included in the study.\n* Unable to sufficiently understand written and spoken Swedish or English to provide written consent and understand information and instructions from the study personal.\n* Pregnant, lactating or planning a pregnancy during the study period.\n* Blood donation or participation in a clinical study with blood sampling within 30 days prior to screening visit and throughout the study.\n* History of gastrointestinal conditions or major gastrointestinal surgery (Inflammatory bowel disease, Crohn's disease, malabsorption, colostomy, bowel resection, gastric bypass surgery etc.).\n* Type 1 diabetes or type 2 diabetes.\n* Thyroid disorder.\n* Current smoking, vaping.\n* Following any weight reduction program or having followed one during the last 6 months prior to screening.\n* Not habitually eating breakfast (\\\u003C5 times\u002Fweek).\n* Restrained eating based on the three-factor eating questionnaire.","50 Years",{"count":180,"type":24},24,[27],"The overall aim of this project is to study the effects of short-term high ultra-processed food intake, compared to nutrient- and energy density matched low ultra-processed food (UPF) intake, on energy intake and appetite.\n\nA total of 24 men and women who meet all inclusion criteria and none of the exclusion criteria will be invited to participate. A randomized 2\\*2 factorial four-way crossover study will be conducted at the Department of Internal medicine and Clinical Nutrition at the University of Gothenburg, comparing a high-UPF meal to a low-UPF meal also with high and\u002For low energy density. A supervised breakfast meal will be served, and postprandial blood samples and appetite measures will be collected continuously up to 4 hours after the breakfast meal. Subsequently, an ad libitum lunch meal will be served, and energy intake will be recorded.",[184,185],"Appetite","Obesity and Obesity-related Medical Conditions","2025-12-12",{"date":188,"type":39},"2025-12-15",{"date":190,"type":39},"2025-12-01",{"date":192,"type":24},"2026-04-30",{"name":45,"class":46},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":202,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":25,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":47},"100612978","hifem-for-incontinence-after-menopause-high-intensity-focused-electromagnetic-hifem-100612978","NCT07260604","HIFEM for Incontinence After Menopause High-Intensity Focused Electromagnetic (HIFEM)","Randomized Trial on Pelvic Floor Training With and Without HIFEM for Stress Urinary Incontinence","HIM2025","Inclusion Criteria:\n\n* Women aged 65-85 ears\n* Having daily stress incontinence requiring use of incontinence aids.\n* Living in ordinary housing without home (health-) care\n* Being physically active and can move independently both indoors and outdoors.\n* Being able to give independent informed consent in speech and writing\n* To understand and follow instructions in one of following languages Swedish, Arabic, French, and\u002For English\n\nExclusion Criteria:\n\n* -Ongoing coached pelvic floor training\n* Heart disease where treatment is contraindicated\n* Lung disease with chronic cough\n* Pacemaker, defibrillator, neurostimulator, medication pump, and implanted devices in the head or spinal cord\n* Electronic or metal implants in the abdomen, hips, or knees\n* Epilepsy\n* Ongoing cancer\n* Stoma or abdominal hernia\n* Ongoing treatment with anticoagulants such as warfarin, medicines affecting the bladder such as muscarin receptor antagonist, diuretics and local oestrogen which affect the bladder and urine production.\n* infection, fever, bleeding, or pain in the lower abdomen\n* Skin diseases or any skin sensitivity\n* BMI exceeding 30 kg\u002Fm2","FEMALE","65 Years","85 Years",{"count":88,"type":24},[27],"It is not difficult to imagine that leaking urine affects life in many contexts. Unfortunately, it is everyday life for far too many people in our society. According to the National Board of Health and Welfare, incontinence primarily affects older people, and both women and men are vulnerable. In Sweden, just over 530,000 people over the age of 65 have problems and almost 80 percent of all people in special housing have such urine leakage that they need to use incontinence aids. First-line treatment for women with incontinence is local estrogen and pelvic floor training. Surgery may also be considered if this treatment does not provide sufficient effect.\n\nA new type of treatment for stress, urge and mixed incontinence is now on the market, High-Intensity Focused Electromagnetic (HIFEM®) treatment. This involves electromagnetic stimulation that causes contractions in the pelvic floor muscles. The treatment is not painful or invasive and the patient sits clothed in the treatment chair. In Sweden, HIFEM® is mainly available outside of traditional healthcare and is very expensive. It is also often given by unauthorized actors.\n\nWe are now planning a study whose purpose is to evaluate the effect of HIFEM® on women over 65 years of age with stress incontinence. A group of 100 women will be randomized to:\n\n1. Standard treatment, i.e. physiotherapy-led pelvic floor training\n2. As above with the addition of 10 treatments of 30 minutes with HIFEM®.\n\nThe evaluation will be carried out regarding leakage, need for incontinence aids and pelvic floor strength immediately and six months after the intervention. The women will also rate their incontinence symptoms, physical activity level, physical function and quality of life. A group will also be interviewed about their experiences of living with incontinence and the treatment. Before the study start, a case study will be performed in which 10 women will be included. They will receive 10 treatments and measure, with the same outcomes, the effects.\n\nAlternative treatment methods are important to meet the care needs we have today but also in the future. If treatment with HIFEM® can be effective for women over 65, it could, in addition to reducing incontinence problems and the consequences of these problems, also lead to reduced costs for society regarding care and incontinence products, as well as reduced environmental impact.",[209],"Urinary Incontinence (UI)",[211,212,213],"urinary incontinence","pelvic floor training","HIFEM-treatment","2025-11-21",{"date":216,"type":39},"2025-12-03",{"date":218,"type":24},"2026-10-15",{"date":220,"type":24},"2028-06-30",{"name":45,"class":46},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":19,"minAge":203,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":25,"phases":231,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":246,"leadSponsor":248,"locationsCount":4},"100606229","non-invasive-diagnostics-of-shunt-obstruction-in-adult-hydrocephalus-100606229","NCT07172841","Non-invasive Diagnostics of Shunt Obstruction in Adult Hydrocephalus","Randomized Controlled Study on Non-invasive Diagnostics of Shunt Obstruction in Adult Hydrocephalus","Inclusion Criteria:\n\n* Patients with normal pressure hydrocephalus (NPH)\n* Treated at either the Hydrocephalus Research Unit in Gothenburg or at the Department of Neurological Surgery at Linköping University Hospital or Sahlgrenska University Hospital\n\nExclusion Criteria:\n\n* Unable to conform to instructions of the study",{"count":230,"type":24},60,[27],"The goal of this RCT is to test whether volumetric assessment of magnetic resonance imaging (MRI) could diagnose shunt obstruction in Adult Hydrocephalus patients, and in addition to explore correlations of blood biomarkers surrounding shunt obstruction. Thirdly to investigate correlations with clinical symptom burden before and after surgery.\n\nThe main questions it aims to answer are:\n\nCan volumetric assessment of cerebrospinal fluid (CSF) aid in diagnosis of shunt obstruction? Are there dynamical changes in blood biomarker concentrations after shunt obstruction? How are clinical symptom burden and dynamics correlated with blood biomarker changes and volumetric changes in CSF?\n\nAfter three months of shunt treatment, researchers will compare patients with \"Virtual OFF\" setting, to explore if simulated shunt obstruction affect measures mentioned above.\n\nParticipants randomized to the intervention group will undergo the 'Virtual OFF' setting for a period of 5-7 days, starting 3 months after initiation of shunt treatment. Symptom burden will be assessed preoperatively, at follow-up, and following the week of the shunt setting change. MRI scans will be conducted at these same time points. Participants in the control group will also meet with a nurse, but their shunt settings will remain unchanged. The control group will receive the same symptom assessments and MRI scans as the intervention group.",[234,235],"Normal Pressure Hydrocephalus Patients","Normal Pressure Hydrocephalus",[237,238,239,240,241],"Volumetry","Shunt obstruction","Shunt patency","NPH","Outcome","2025-09-08",{"date":244,"type":39},"2025-09-15",{"date":244,"type":24},{"date":247,"type":24},"2034-12-31",{"name":45,"class":46},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":202,"minAge":56,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":47},"100578052","respiration-after-robot-assisted-laparoscopic-hysterectomy-100578052","NCT06806280","Respiration After Robot Assisted Laparoscopic Hysterectomy","Respiration Efter Hysterektomi Med Robotassisterad Laparoskopi- REHYR","REHYR","Inclusion Criteria:\n\n* ≥18 years of age undergoing robotic-assisted laparoscopic hysterectomy for endometrial cancer or endometrial intraepitelial neoplasty..\n\nExclusion Criteria:\n\n* cognitive impairment and difficulty understanding Swedish or English instructions.",{"count":258,"type":24},80,"The study will investigate how respiratory function is affected by robot-assisted surgery. Previous studies have investigated the impact after open and laparoscopic surgery, but there are no studies yet after robot-assisted surgery.\n\n80 women undergoing robot-assisted hysterectomy will undergo measurements of lung function and oxygen saturation before and after the operation.",[261],"Cancer Uterus Cervix",[263,264,265],"respiration","hysterctomy","robot assisted surgery","2025-08-20",{"date":268,"type":39},"2025-08-21",{"date":270,"type":39},"2025-03-17",{"date":272,"type":24},"2026-06-30",{"name":45,"class":46},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":25,"phases":283,"briefSummary":284,"conditions":285,"keywords":288,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":47},"100536859","use-of-a-bone-substitute-material-in-the-surgical-therapy-of-furcation-defects-100536859","NCT06270303","Use of a Bone Substitute Material in the Surgical Therapy of Furcation Defects","The Use of a Bone Substitute Material in the Surgical Therapy of Furcation Defects - a Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\nPatients should present with at least one surgically accessible molar (in tooth position 6 or 7) diagnosed with a single furcation defect degree II (at any aspect).\n\nFollowing initial periodontal therapy, teeth to be included should present with one site with furcation defect degree II in combination with:\n\n* Bleeding on probing\n* Probing pocket depth of ≥6 mm\n* Soft tissue coverage of the furcation entrance Patients should present with a full mouth plaque score ≤25%.\n\nExclusion Criteria:\n\n* Multiple deep furcation defects (degree II - III) at the same tooth\n* Vertical attachment loss \\>50% at aspects not facing the furcation defect\n* Defects presenting with apico-marginal communication\n* Intake of systemic antibiotics within 6 months\n* Systemic conditions\u002Fmedication impeding surgical intervention (e.g. uncontrolled diabetes, immunosuppressive medication)",{"count":282,"type":24},200,[27],"The aim of this randomized clinical trial is to evaluate the potential benefit of the use of a bone substitute material in the treatment of furcation degree II-involved molars. The main question it aims to answer is: What is the benefit of the adjunctive use of a bone substitute material in the surgical treatment of furcation degree II-involved molars when compared to open-flap debridement alone?\n\n200 patients with ≥1 molar presenting with a furcation defect degree II will be included and randomized to either control (open-flap debridement) or test treatment (open-flap debridement + bone substitute material). The primary outcome of the study is furcation closure defined as absence of clinically detectable furcation involvement degree \\>I. Secondary outcomes include changes in bleeding on probing, probing depth, vertical and horizontal attachment levels, soft tissue level, marginal bone level, need for surgical retreatment, tooth loss, patient-reported outcomes and adverse events. A composite outcome based on furcation closure (degree ≤I) in combination with shallow probing depth (≤5 mm) and absence of bleeding on probing will also be evaluated.",[286,287],"Periodontitis","Furcation Defects",[289,290,291],"Surgical therapy","Reconstructive","Randomized controlled trial",{"date":268,"type":39},{"date":294,"type":39},"2025-03-27",{"date":296,"type":24},"2037-03-01",{"name":45,"class":46},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":25,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":47},"100518988","effectiveness-of-meshed-free-gingival-graft-for-widening-of-keratinized-tissues-100518988","NCT06037694","Effectiveness of Meshed Free Gingival Graft for Widening of Keratinized Tissues","Widening of Keratinized Tissues With an Expanded Meshed Free Gingival Graft: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n* ≥18 years of age,\n* systemically healthy,\n* presence of ≥2 adjacent implants in both sides of the mandibles showing \\\u003C2 mm of KM on the buccal aspects,\n* subjects have to present with discomfort from brushing and\u002For difficulties in maintaining proper home care due to inadequate dimension of KM\n* Full-Mouth Plaque Score (FMPS) \\\u003C20%,\n* Full-Mouth Bleeding Score (FMBS) \\\u003C20%.\n\nExclusion Criteria:\n\n* pregnancy or lactation,\n* tobacco smoking,\n* uncontrolled medical condition,\n* medication that can affect gingival conditions.","70 Years",{"count":120,"type":24},[27],"The overall objective of this project is to evaluate, over a period of 1 year, the outcomes of either conventional free gingival graft (FGG) or mesh-FGG to increase the width of keratinized mucosa (KM) at implant sites.",[310],"Gingiva Atrophy",{"date":268,"type":39},{"date":313,"type":39},"2024-01-01",{"date":315,"type":24},"2026-08-01",{"name":45,"class":46},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":202,"minAge":56,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":25,"phases":326,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":340,"locationsCount":47},"100450958","transcutaneous-electrical-nerve-stimulation-for-endometriosis-related-chronic-pain-100450958","NCT05152264","Transcutaneous Electrical Nerve Stimulation for Endometriosis-related Chronic Pain","High Frequency, High Intensity Transcutaneous Electrical Nerve Stimulation for Endometriosis-related Chronic Pain - a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥18 years\n* Consents to participation in the study\n* Verified endometriosis (by laparoscopy or ultrasound).\n* Chronic endometriosis-related pain (\\> 3 months), available for TENS treatment\n* Functioning, stable endometriosis-specific hormonal drug therapy. The endometriosis-specific drug therapy must be unchanged for the last 3 months and no gynecological surgical procedures for the treatment of endometriosis are planned during the next 7 months (during study participation). The endometriosis-specific drug therapy does not refer to analgesic therapy for symptom relief of endometriosis-related pain.\n\nExclusion Criteria:\n\n* Patient with inability to understand and use written and spoken Swedish\n* Patient with pacemaker and\u002For ICD or other electronic implants\n* Patient with impaired sensation over the painful area\n* Malignant disease with an expected survival \\\u003C12 months\n* Alcohol or substance abuse\n* Serious untreated psychiatric illness and\u002For psychological condition that is the primary determinant of the patient's condition\n* Participating in another intervention study with possible impact on current study outcome measures\n* Patient who is using \\>90 morphine equivalents\u002Fday\n* Patient who is electro-acupuncture\n* Pregnancy","100 Years",{"count":23,"type":24},[27],"The study evaluates the effect of TENS (transcutaneous electrical nerve stimulation) as add-on treatment compared with conventional analgesic treatment in patients with endometriosis-related chronic pain. Patients with frequent pain and high pain intensity will be randomized to additional treatment with TENS or conventional treatment for 8 weeks to evaluate the acute effects of TENS treatment (n=40). Patients with endometriosis-related pain that is not frequent or without high pain intensity constitute an external control group. All patients in the study will receive TENS treatment for a total of 16 weeks, for evaluation of long-term effects of TENS treatment.",[329],"Endometriosis-related Pain",[331,332,333],"Endometriosis","Chronic pain","Transcutaneous electrical nerve stimulation","2025-05-20",{"date":336,"type":39},"2025-05-23",{"date":338,"type":39},"2021-11-12",{"date":78,"type":24},{"name":45,"class":46},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":21,"enrollmentInfo":349,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":47},"100382102","adipose-inflammation-and-diabetes-fab-100382102","NCT04255264","Adipose Inflammation and Diabetes (FAB)","Adipose Tissue Inflammation and Diabetes Development (Fettvävsinflammation Och Diabetesutveckling)","FAB","Inclusion Criteria:\n\n* BMI 30-40 kg\u002Fm2\n* Ptos (i.e. excess skin) \\> 3 cm\n* Patient underwent gastric bypass surgery \\>2 years ago\n* Patient has had a stable weight ≥6 months at the time of operation\n* Patient does not smoke (min 6 weeks prior to surgery)\n\nExclusion Criteria:\n\n* Patients who do not understand spoken and written Swedish\n* American Society of Anesthesiologists (ASA) classification ≥ 3\n* Neurological, orthopedic or rheumatologic injury or illness affecting physical ability\n* Preoperatively known hernia requiring surgical operation\n* Severe mental illness",{"count":350,"type":24},18,"The study investigates whether the addition of resolution molecules can inhibit inflammation and insulin resistance in human tissue taken from obese individuals, and whether the results of these studies correlate with patient-specific resolution phenotypes.",[353],"Obese","2025-05-05",{"date":356,"type":39},"2025-05-06",{"date":358,"type":39},"2019-08-01",{"date":360,"type":24},"2027-06-30",{"name":45,"class":46},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":203,"enrollmentInfo":370,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":47},"100382184","cardiometabolic-health-and-inflammatory-resolution-100382184","NCT04256330","Cardiometabolic Health and Inflammatory Resolution","Cardiometabolic Health and Inflammatory Resolution (Kardiometabol hälsa Och Inflammatorisk Resolution)","REX","Inclusion Criteria:\n\n* Informed signed consent has been obtained from the volunteer.\n* The volunteer has a BMI greater than 18.5 kg\u002Fm2\n\nExclusion Criteria:\n\n* The study staff contacting a potential participant perceives that the individual has difficulty understanding the information.\n* An MD determines that the individual is on too many medications to participate\n* The individual takes a medication that is approved by the MD, but he\u002Fshe is not willing or not able to wait with any potential morning medication until after their fasted blood-draw.\n* The individual is younger than 18 years (relevant for the FAINT-1 and FAINT-2 cohorts)\n* The individual states that they have increased bleeding tendency or are using anti-coagulant (blood thinning) medication.\n* The individual has some form of chronic inflammation.\n* The individual regularly uses medication that affects inflammatory resolution (e.g., low-dose aspirin).\n* The individual uses immunosuppressive drugs (eg, methotrexate).\n* The individual regularly consumes fish oils (omega 3).\n* The individual has significant gastrointestinal problems.\n* The individual smokes or uses chewing tobacco.\n* The individual has been drinking alcohol two days before the study visit.\n* The individual has tattoos or body piercings on the forearms and \u002F or the stomach that can affect the examination.\n* The individual does not follow instructions given in the research study.",{"count":282,"type":24},"The aim of this study is to determine how inflammatory resolution impacts cardiometabolic health and disease in subjects that are either lean (18.5-24.9 kg\u002Fm2), overweight (25.0-29.9 kg\u002Fm2) or obese (\\>30.0 kg\u002Fm2).",[373],"Volunteers",{"date":375,"type":39},"2025-05-08",{"date":377,"type":39},"2020-01-23",{"date":379,"type":24},"2027-09-01",{"name":45,"class":46},{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":18,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":47},"100341978","inflammation-in-vascular-disease-100341978","NCT03732612","Inflammation in Vascular Disease","The Role of Inflammation in Vascular Disease (Inflammationens Roll i kärlsjukdom)","REBEL","Inclusion Criteria:\n\n* Patient is planned to undergo vascular surgery.\n* Signed informed consent has been obtained from the patient.\n\nExclusion Criteria:\n\n* Patient has difficulty to understand information.\n* Patients under 18 years of age.\n* Patients participating in any drug-related study.",{"count":390,"type":24},170,"Increasing evidence suggests that systemic low-grade inflammation may be a driving force of cardiometabolic complications, such as vascular dysfunction, atherosclerosis and ischemic heart disease. Thus, we will investigate the role of inflammation in cardiovascular disease.",[393,394],"Vascular Diseases","Atherosclerosis",{"date":356,"type":39},{"date":397,"type":39},"2019-09-02",{"date":399,"type":24},"2027-02-01",{"name":45,"class":46},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":21,"enrollmentInfo":409,"targetDuration":4,"studyType":25,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":47},"100208023","sleeve-gastrectomy-and-roux-en-y-gastric-bypass-in-the-treatment-of-type-2-diabetes-mellitus-100208023","NCT01984762","Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus.","Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus. Randomised Controlled Trial","CONTROL","Inclusion Criteria:\n\n1. Type 2 diabetes mellitus\n2. BMI between 35 and 50kg\u002Fm2.\n3. Males and females\n4. Age between 18 and 60 years.\n\nExclusion Criteria:\n\n1. Severe ongoing psychiatric disorder, alcoholism and substance abuse.\n2. Redo operations after previous bariatric procedures.\n3. Type 1 diabetes or other non-type 2 forms of diabetes\n4. End stage renal disease, retinopathy, neuropathy",{"count":410,"type":24},134,[27],"Obesity is a growing epidemic throughout the world and is followed by increasing incidence of type 2 diabetes that accounts for 90-95% of all cases of diabetes. Weight loss is a major objective, although difficult to achieve with medical treatments. Many recent studies demonstrated that bariatric surgery has the potency to achieve marked and sustained weight loss, and is also associated with a significant improvement in control of type 2 diabetes. The principal aim of this study is to compare two types of bariatric procedures, the Roux-en-Y gastric bypass (RYGBP) and sleeve gastrectomy (SG). The study hypothesis is that these procedures have equal efficacy with regard to resolution of type 2 diabetes.",[150,414,415],"Type 2 Diabetes","Bariatric Surgery","2025-04-24",{"date":418,"type":39},"2025-04-25",{"date":420,"type":39},"2012-09",{"date":422,"type":24},"2025-10-10",{"name":45,"class":46},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":18,"sex":19,"minAge":432,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":25,"phases":436,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":449},"100536681","the-effectiveness-of-early-intervention-to-correct-the-position-of-pdcs-100536681","NCT06267989","The Effectiveness of Early Intervention to Correct the Position of PDC:s","The Effectiveness and Cost-effectiveness of Early Intervention to Correct the Position of a Palatally Displaced Maxillary Permanent Canine: A Multicentre RCT","PDC","Inclusion Criteria:\n\n* One or both upper permanent canine teeth are not palpable or there is a pronounced difference in the eruption between the left and right side. Dental radiographs will be taken to confirm that the permanent tooth is displaced. Canines in sector 5 are going to be excluded from this trial.\n\nExclusion Criteria:\n\n* Buccal displacement of the canine(s), missing permanent lateral incisors; severe upper arch dental crowding (\\>2mm in each affected quadrant) or associated pathology.","10 Years","12 Years",{"count":435,"type":24},324,[27],"Approximately 2-3% of children will have problems with one or both of their permanent or 'adult' canine teeth in the upper jaw. These canine teeth sometimes fail to erupt properly, because they are displaced into the roof of the mouth or palate. These are known as palatally displaced canines, PDC, (Brin et al., 1986, Ericson and Kurol, 1987). In addition to failing to erupt, displaced teeth can cause problems, such as damage to the roots or displacement of the neighbouring teeth (Ericson and Kurol, 1988a, Ericson and Kurol, 2000, Falahat et al., 2008).\n\nIt has been suggested that if the primary ('baby' or 'milk') canine is extracted at an appropriate time in a child with a suspected palatally displaced canine, then the displaced tooth might spontaneously correct its position (Ericson and Kurol, 1988b) and the extraction of the baby canine when a clinician suspects that the adult canine is displaced has become accepted clinical practice (Short, 2009). This appears to be on the basis of one report of a series of 35 children who received the intervention and no control group (Ericson and Kurol, 1988b). Two recent systematic reviews have examined the evidence for the effectiveness of removal of the primary canine with the aim of correcting the eruption path of a palatally displaced canine. A recent systematic review published in The Cochrane Library in 2021 (Benson et al., 2021) noted that the evidence for any intervention to correct the eruption path of a displaced permanent canine is weak and further research is required. Numerous problems with the reported studies were identified by both reviews.\n\nOther authors have suggested that using a RME (Rapid Maxillary expansion) or headgrear (EOT) to create sufficient space within the dental arch for the permanent canine tooth will encourage the tooth to erupt (Baccetti et al., 2011). This approach might be less traumatic to a child who may have had no experience of dental treatment, other than routine check-ups. If either or both approaches are shown to be effective then their widespread use would be advantageous to both the child and the healthcare provider, because the need for an operation, under general anaesthetic, to uncover the tooth and extensive brace treatment to straighten the tooth will be avoided.",[439,440,441],"Ectopic Tooth Eruption","Palatal Expansion Technique","Randomized Clinical Trial","2025-04-22",{"date":416,"type":39},{"date":445,"type":39},"2024-10-01",{"date":447,"type":24},"2027-12-30",{"name":45,"class":46},3,{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":458,"targetDuration":432,"studyType":89,"phases":4,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":473,"locationsCount":47},"100297485","basun---risks-for-malnutrition-metabolic-bone-disease-and-impaired-oral-health-after-obesity-treatment-100297485","NCT03152617","BASUN - Risks for Malnutrition, Metabolic Bone Disease and Impaired Oral Health After Obesity Treatment","BASUN - Risks for Malnutrition, Metabolic Bone Disease and Impaired Oral Health After Obesity Treatment - Interaction With Gastrointestinal Microbiota, Psychiatric Morbidity and Socioeconomics","BASUN","Inclusion Criteria:\n\n* All patients eligible for obesity treatment under specialist care with medical methods or with surgery\n\nExclusion Criteria:\n\n* no ability to speak, read or write in Swedish",{"count":459,"type":24},1400,"Weight-reducing obesity surgery (OS) generally gives good results but complications are common; e.g. impaired weight loss, weight regain, bowel pain, diarrhea, vitamin\u002Fmineral deficiency, osteoporosis and impaired dental health. The BASUN study is a prospective 10-year comparison of 1000 surgically and 400 conventionally treated individuals regarding adverse side-effects, risk factors for complications and poor outcome.",[462],"Obesity, Morbid",[154,464,465,466,467],"gastric bypass","malnutrition","bone disease","oral health",{"date":469,"type":39},"2025-04-23",{"date":471,"type":4},"2015-04",{"date":43,"type":24},{"name":45,"class":46},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":25,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":170},"100322725","evaluation-of-an-oral-care-programme-for-head-and-neck-cancer-patients-100322725","NCT03481647","Evaluation of an Oral Care Programme for Head and Neck Cancer Patients","Evaluation of an Oral Care Programme for Patients Undergoing Treatment for Head and Neck Cancer Regarding Mucositis, Oral Health, Epigenetic Modifications, Patient-related Factors, Quality of Life and Health Economy","Inclusion Criteria:\n\n* Patients scheduled to receive full dose of curative RT including major salivary glands in the radiation field\n\nExclusion Criteria:\n\n* Patients with recurrent cancer\n* Patients with severe cognitive impairment.","80 Years",{"count":483,"type":24},150,[27],"This study will evaluate the effect of an intensified oral care programme on prevalence, severity and duration of mucositis in patients undergoing treatment for cancer in the head and neck region.\n\nPatients in the control group get professional oral care once a week.",[487],"Head and Neck Cancer","2025-04-16",{"date":490,"type":39},"2025-04-20",{"date":492,"type":39},"2018-01-08",{"date":494,"type":24},"2026-12-31",{"name":45,"class":46},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":19,"minAge":503,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":25,"phases":505,"briefSummary":506,"conditions":507,"keywords":511,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":519,"locationsCount":47},"100544422","bridging-the-gap-creating-a-continuum-of-care-100544422","NCT06368674","Bridging the Gap: Creating a Continuum of Care","Bridging the Gap: Creating a Continuum of Care Through Active Follow-up by a Case Manager After Discharge - a Controlled Study","Inclusion Criteria:\n\n75 years or older, screened as frail, admitted to an acute geriatric ward working according to CGA at the Sahlgrenska or Mölndal hospital. Both hospitals are part of Sahlgrenska University hospital, with the same catchment area, including Gothenburg with surrounding municipalities. People in the region can seek care at both hospitals. The orthopaedic clinic is situated at Mölndal hospital, resulting in most patients with fractures being admitted to this hospital, irrespective of in which municipality they are living. Cognitive impairment is not an exclusion criterion. For people who cannot give informed consent due to cognitive impairment, next of kin will be asked to assist with the consent.\n\nExclusion Criteria:\n\nLess that 75 years old, Not residing in a permanent residence.","75 Years",{"count":483,"type":24},[27],"Coordination and integration between care settings is essential for the quality of care of frail older patients. An active follow-up by a case manager (CM) after discharge form an acute geriatric hospital ward has the potential to bridge the gap between hospital, primary and municipality care for frail older people. This study evaluates the effects of an active follow-up by a CM in primary care after discharge from a geriatric ward, with the following research questions: Can an active follow-up by CM for frail older people discharged from an acute geriatric ward, compared to those not receiving active follow up, Maintain\u002Fincrease independence in activities of daily living, self-rated health and life satisfaction? Increase satisfaction with health care? Reduce health care consumption\u002Fbe cost-effective? How feasible is the intervention and the study design from the perspective of the caregivers and the older person? This is a clinical controlled study with a process evaluation. Inclusion criteria are 75 years or older, frail and admitted to a geriatric ward.\n\nThis study is relevant since today's highly specialized acute care is poorly adapted to the comprehensive needs of frail older people, and exposes them to avoidable risks such as loss of functional capacities causing unnecessary care needs and decreased wellbeing. Active follow-up by a CM after discharge may be an important way to integrate the care for frail older people, after receiving in-hospital geriatric care. This can improve the quality of care for this vulnerable group, and direct the right health care actions towards those in most need.\n\nThe intervention is a active follow-up after discharge by a CM (nurse) in primary care. CM will secure that discharge and care plans are executed and to address new needs. If there are unmet needs, the CM will ensure that adequate actions are performed to meet the needs. The intervention group consists of participants discharged to a primary health care centre with a CM, who actively follows-up after discharge. The control group consists of participants discharged to a primary health care centre without CM, and thereby no active follow-up after discharge. All participants will be followed-up by the research team during one year, concerning dependence in activities of daily living, self-rated health, health care consumption and satisfaction with care.",[508,509,510],"Frailty","Dependence","Integrated Care",[512],"Person-centred care","2025-04-09",{"date":515,"type":39},"2025-04-11",{"date":517,"type":39},"2024-06-06",{"date":399,"type":24},{"name":45,"class":46},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":19,"minAge":528,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":25,"phases":531,"briefSummary":532,"conditions":533,"keywords":536,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":546,"locationsCount":4},"100544423","tranpas---treating-anorexia-nervosa-plus-autism-spectrum-100544423","NCT06368687","TRANPAS - TReating Anorexia Nervosa Plus Autism Spectrum","Anorexia Nervosa and Autism - a Care Location Adapted for Both Conditions","TRANPAS","Inclusion Criteria:\n\n* 25 years or older\n* Meeting criteria for both anorexia nervosa and autism spectrum disorder according to the DSM-5\n* In need of inpatient care due to anorexia nervosa\n\nExclusion Criteria:\n\n* 24 years or younger\n* Not in need of inpatient care due to anorexia nervosa\n* Not meeting criteria for both anorexia nervosa and autism spectrum disorder according to the DSM-5","25 Years",{"count":530,"type":24},10,[27],"In a pilot study, the investigators will validate a so-called autism care location in an inpatient ward. The care location will be adapted for patients with anorexia nervosa (AN) and concurrent autism (AN+autism). In order to investigate the effect of a tailored care location for patients with AN + autism, the evaluation will include weight development and changes in nutritional intake, eating disorder and anxiety symptoms. The overall aim is to improve treatment for this specific AN subgroup, that otherwise has a worse prognosis regarding AN recovery.",[534,535],"Anorexia Nervosa","Autism Spectrum Disorder",[537,538,539,540],"anorexia nervosa","autism","pilot study","validation","2025-04-07",{"date":513,"type":39},{"date":544,"type":24},"2025-08-15",{"date":494,"type":24},{"name":45,"class":46},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":305,"enrollmentInfo":555,"targetDuration":4,"studyType":25,"phases":556,"briefSummary":557,"conditions":558,"keywords":560,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":449},"100500538","unilateral-primary-aldosteronism-mineralocorticoid-antagonists-versus-surgical-treatment-100500538","NCT05797558","Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment","Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment - A Randomized Controlled Trial","UPA-MEST","Inclusion Criteria:\n\n1. Patients with confirmed unilateral PA\n2. Age 18-70 years\n3. Candidate for surgical treatment\n4. No contraindications for minimally invasive surgery or treatment with MRA\n5. Understands oral and written information and provides oral and written informed consent.\n\nExclusion Criteria:\n\n1. Unwilling or unable to undergo surgery\n2. Unwilling to accept medical treatment for 12 months and not receiving standard treatment (surgery)\n3. Impaired renal function with eGFR \\\u003C45 ml\u002Fmin\u002F1,73m2\n4. P-cortisol \\>138 nmol\u002FL following 1-mg overnight dexamethasone suppression test.",{"count":258,"type":24},[27],"This is a prospective randomized controlled trial where quality of life and the effectiveness of treatment will be evaluated in 80 patients with confirmed unilateral primary aldosteronism ,randomly assigned to be either treated surgically with unilateral adrenalectomy or to receive medical treatment with eplerenone.",[559],"Primary Hyperaldosteronism Due to Adrenal Adenoma",[561,562,563,564,565,566,567,568,569],"hyperaldosteronism","primary aldosteronism","lateralized aldosteronism","unilateral aldosteronism","eplerenone","spironolactone","randomized trial","quality of life","PASO outcomes","2025-04-03",{"date":572,"type":39},"2025-04-06",{"date":574,"type":39},"2023-04-28",{"date":576,"type":24},"2028-05-28",{"name":45,"class":46},{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":19,"minAge":586,"maxAge":587,"enrollmentInfo":588,"targetDuration":4,"studyType":25,"phases":589,"briefSummary":590,"conditions":591,"keywords":595,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":47},"100395788","pictorial-support-in-person-centred-care-for-children-picpecc-100395788","NCT04433650","Pictorial Support in Person-centred Care for Children (PicPecc)","A Person-centred Approach to Pictorial Support in Care for Children (PicPecc)","PicPecc","Inclusion Criteria:\n\n* Children with cancer, 5-17 years\n* The children´s legal guardians\n* Healthcare professionals who take care of these children\n* The child needs to have a cognitive level of approximately five years (i.e., be able to understand a numeric rating scale (NRS)).\n\nExclusion Criteria:\n\n\\- Children 0-4 years","5 Years","17 Years",{"count":23,"type":24},[27],"Introduction: Person-centred care is based on the assumption that every person has resources that should be used in the care situation. In order for this to happen the patient has to be able to effectively communicate his\u002Fher symptoms. This protocol describes the analysis of a digital picture-based tool for communication support for children with cancer aged 5-17 years, who undergo high-dose methotrexate treatment. The advantage of a non-linguistic based platform, beside the expected clinical outcomes, is that it can be used in multiple national studies with minimal translation.\n\nMethods and analysis: Two studies will be conducted in a hybrid design, i.e., a crossover design will be used for the intervention (effects), and a mixed-methods design will be used for the process evaluation. Qualitative interviews will be carried out with children with cancer, their legal guardians and case-related healthcare professionals as part of the process evaluation.\n\nThe interviews will address the experiences of the intervention and frequency of use from the child's perspective. Interview transcripts will be analyzed qualitative descriptively. The digital communication tool will collect child self-reports of symptoms\u002Femotions. The children will be monitored for biomarkers of stress and pain (neuropeptides, neurosteroids and peripheral steroids) in venous blood samples, in-app estimation levels for the children, drug consumption. Person-centeredness will be evaluated with the questionnaire Visual CARE Measure.\n\nEthics: Ethical approval was obtained from the Swedish Ethical Review Authority (ref 2019-02392; 2020-02601).",[592,593,594],"Childhood Cancer","Communication","Symptoms and Signs",[596,593,597,598,599,594],"Childhood cancer","Digital application","Intervention","Pictorial support",{"date":572,"type":39},{"date":602,"type":39},"2021-04-01",{"date":494,"type":24},{"name":45,"class":46},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":19,"minAge":203,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":25,"phases":614,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":47},"100557419","icbt-for-seniors-with-depression-in-primary-care-100557419","NCT06537869","iCBT for Seniors With Depression in Primary Care","The New Internet Generation: iCBT Treatment for Seniors With Mild-moderate Depression - a Pragmatic Randomised Controlled Trial in the Primary Care Context","Inclusion Criteria:\n\n* All patients \\>65, attending PCCs engaged in the trial, with mood as well as somatic complaints will be asked about depressive symptoms during the last 2 weeks by NICE guidelines for depression.\n* All patients diagnosed with minor\u002Fmajor depression and not belonging to exclusion criteria and willing to take part in the trial will be diagnosed via the Mini International Neuropsychiatric Interview (M.I.N.I.) by a psychologist\u002Fspecially trained nurse and have a General Practitioner (GP) somatic consultation\n\nExclusion Criteria:\n\nPatients diagnosed with:\n\n* severe depression\n* prior suicide attempt or currently at medium to high risk of suicide (MADRS-S question 9\\>3 points or MINI suicide \\>9)\n* bipolar disorder\n* psychosis\n* addiction\n* cognitive impairment\n* not speaking or understanding Swedish.",{"count":613,"type":24},390,[27],"This clinical trial aims to evaluate the potential benefits of internet cognitive behavioural therapy (iCBT) for elderly patients with mild\u002Fmoderate depression and compare its effectiveness with the current treatment as usual (TAU) at primary care centres (PCCs).\n\nThe specific aims are to study if:\n\niCBT is as effective as TAU in reducing depressive symptoms iCBT is as effective as TAU in increasing quality of life iCBT is as effective as TAU in increasing the function in patients \\>65 years and older with mild\u002Fmoderate depression attending primary care, with the perspective of 36 months.\n\nParticipants will:\n\nWork with the iCBT program (10-12 weeks) or become TAU at their PCCs. Followed-up at 3, 6, 12, 24 and 36 months of their symptoms, quality of life and function.",[617,618],"Depression Mild","Depression Moderate","2025-03-31",{"date":621,"type":39},"2025-04-01",{"date":623,"type":39},"2024-09-01",{"date":625,"type":24},"2029-06",{"name":45,"class":46},{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":18,"sex":202,"minAge":56,"maxAge":4,"enrollmentInfo":634,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":636,"conditions":637,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":639,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":47},"100478275","exploring-central-sensitization-in-pregnant-women-100478275","NCT05507853","Exploring Central Sensitization in Pregnant Women","In the Joints or in the Brain? Exploring Central Sensitization in Pregnant Women and Its Role in Pain, Physical Activity, Functioning and Health Following Pregnancy","Inclusion Criteria:\n\n* pregnant (first time pregnant or previous experience of pregnancy)\n* 18 years of age or older\n* have a single foetus pregnancy\n* be in gestational weeks 20-30\n* able to read and understand Swedish or English\n\nExclusion Criteria:\n\n* no history of a fracture or malignant disease in the back, pelvis, pelvic floor or hips\n* no systemic disease of the musculoskeletal or the nervous system\n* no diseases such as gestational diabetes or diabetes type 1 and 2, hypertension\n* no obstetric complications\n* no contradiction for tests.",{"count":635,"type":24},144,"Pelvic Girdle Pain (PGP) is reported by 50% of pregnant women and up to 11 years after pregnancy, 10% of women have persistent and per definition chronic PGP. Central (nervous system) sensitization that elicits pain hypersensitivity, may be one explanation.\n\nThe overall aim of this study is to explore features of central sensitization in pregnant women and its predictive ability on physical activity, functioning and health in women with PGP. Measurements of central sensitization will be done on two study groups, pregnant women with PGP and healthy controls. To identify women at risk to develop chronic pain in relation to a common pain experience ie PGP in pregnancy, may help us understand if central sensitization early in life explains why women develop chronic pain.",[638,92],"Pelvic Girdle Pain",{"date":621,"type":39},{"date":641,"type":39},"2023-08-15",{"date":643,"type":24},"2025-12-31",{"name":45,"class":46},""]